100mg tablets (AUST R 128635). 200mg tablets (AUST R 104279). 400mg tablets (AUST R 104280).
Reasons the product is recalled
The Therapeutic Goods Administration has cancelled the registration of Lumiracoxib because of serious liver side effects associated with the use of the drug.
The hazards to consumers
Potentially life-threatening or could cause a serious risk to health (Class I).
What consumers should do
Patients taking Lumiracoxib should stop taking the medicine now and discuss alternative treatments with their doctor.
Novartis Pharmaceuticals Australia Pty Ltd
Where the product was sold